Applied Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Employees
- 25
- Market Cap
- -
Clinical Trials
5
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
Confirmatory Study of Govorestat in CMT-SORD
- Conditions
- Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD)
- Interventions
- Drug: Placebo Control
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT07191912
- Locations
- πΊπΈ
University of Iowa, Iowa City, Iowa, United States
πΊπΈClinic for Special Children, Gordonville, Pennsylvania, United States
π¦πΊSydney Childrens, Sydney, Australia
AT-007 in Adult Subjects With Classic Galactosemia (CG)
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05418829
- Locations
- πΊπΈ
Hassman Research Institute, Berlin, New Jersey, United States
A phase 2/3 study to evaluate efficacy and clinical benefit of AT-007 with Sorbitol Dehydrogenase (SORD) Deficiency
- Conditions
- Sorbitol Dehydrogenase (SORD) Deficiency
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Applied Therapeutics Inc.
- Target Recruit Count
- 45
- Registration Number
- 2024-518250-16-00
- Locations
- πΊπΈ
University of Colorado, Aurora, Colorado, United States
πΊπΈUniversity of Miami, Coral Gables, Florida, United States
πΊπΈUniversity of Iowa, Iowa City, Iowa, United States
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04902781
- Locations
- πΊπΈ
Children's Hospital Colorado, Aurora, Colorado, United States
πΊπΈRare Disease Research Center, Atlanta, Georgia, United States
πΊπΈUniversity of Michigan, Ann Arbor, Michigan, United States
Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT04117711
- Locations
- πΊπΈ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
πΊπΈAtlanta Center for Medical Research, Atlanta, Georgia, United States
πΊπΈBrigham and Women's Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next
News
BridgeBio's Attruby Approved for ATTR-CM, Cassava's Simufilam Fails in Alzheimer's Trial
BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization.